Literature DB >> 3263965

An increase in intracellular free Ca2+ associated with serum-free growth stimulation of Swiss 3T3 fibroblasts by epidermal growth factor in the presence of bradykinin.

R Olsen1, K Santone, D Melder, S G Oakes, R Abraham, G Powis.   

Abstract

Bradykinin gave a biphasic increase in intracellular free Ca2+ concentration ([Ca2+]i) in serum-deprived Swiss 3T3 fibroblasts loaded with the photoprotein aequorin. Epidermal growth factor (EGF) alone did not increase [Ca2+]i, but when added after bradykinin there was an increase in [Ca2+]i. The EGF-dependent increase in [Ca2+]i was maximal at 3 min and disappeared with a half-life of 6 min after bradykinin. Removing Ca2+ from the external medium did not abolish either the bradykinin or the EGF-induced [Ca2+]i responses. Although prostaglandins E2 and F2 alpha also gave [Ca2+]i responses and permitted an EGF-dependent [Ca2+]i response, the effect of bradykinin did not appear to be mediated by prostaglandins since it was not blocked by indomethacin. Vasopressin and phorbol 12-myristate 13-acetate both gave a [Ca2+]i response but did not facilitate a [Ca2+]i response by EGF. Bradykinin or EGF alone did not increase DNA synthesis in growth-arrested Swiss 3T3 fibroblasts, but EGF added together with, or after, bradykinin increased DNA synthesis. The effect disappeared with a half-life of 180 min after the addition of bradykinin. It is concluded that stimulation of receptor protein tyrosine kinase is unlikely, by itself, to explain the increase in DNA synthesis produced by EGF. The observed increase in [Ca2+]i caused by EGF after bradykinin probably reflects the interaction of intracellular second messenger pathways leading to facilitation of DNA synthesis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263965

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Alterations of G-protein coupling function in phosphoinositide signaling pathways of cells transformed by ras and other membrane-associated and cytoplasmic oncogenes.

Authors:  T Alonso; S Srivastava; E Santos
Journal:  Mol Cell Biol       Date:  1990-06       Impact factor: 4.272

2.  Expression cloning of a rat B2 bradykinin receptor.

Authors:  A E McEachern; E R Shelton; S Bhakta; R Obernolte; C Bach; P Zuppan; J Fujisaki; R W Aldrich; K Jarnagin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

3.  Increased intracellular Ca2+ signaling caused by the antitumor agent helenalin and its analogues.

Authors:  G Powis; A Gallegos; R T Abraham; C L Ashendel; L H Zalkow; G B Grindey; R Bonjouklian
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Ca2+ responses to interleukin 1 and tumor necrosis factor in cultured human skin fibroblasts. Possible implications for Reye syndrome.

Authors:  B E Corkey; J F Geschwind; J T Deeney; D E Hale; S D Douglas; L Kilpatrick
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

5.  Bradykinin induces a B2 receptor-mediated calcium signal linked to prostanoid formation in human gingival fibroblasts in vitro.

Authors:  U H Lerner; G Brunius; I Andurén; P O Berggren; L Juntti-Berggren; T Modéer
Journal:  Agents Actions       Date:  1992-09

6.  D-3-deoxy-3-substituted myo-inositol analogues as inhibitors of cell growth.

Authors:  G Powis; I A Aksoy; D C Melder; S Aksoy; H Eichinger; A H Fauq; A P Kozikowski
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

7.  Inhibition of growth factor binding, Ca2+ signaling and cell growth by polysulfonated azo dyes related to the antitumor agent suramin.

Authors:  G Powis; M J Seewald; D Melder; M Hoke; C Gratas; T A Christensen; D E Chapman
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 8.  Development biology of the renal kallikrein-kinin system.

Authors:  S S el-Dahr
Journal:  Pediatr Nephrol       Date:  1994-10       Impact factor: 3.714

9.  Cellular pharmacology of D-3-azido-3-deoxy-myo-inositol, an inhibitor of phosphatidylinositol signaling having antiproliferative activity.

Authors:  G Brunn; A H Fauq; S Chow; A P Kozikowski; A Gallegos; G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

10.  Synergism between the contractile effect of epidermal growth factor and that of des-Arg9-bradykinin or of alpha-thrombin in rabbit aortic rings.

Authors:  D deBlois; G Drapeau; E Petitclerc; F Marceau
Journal:  Br J Pharmacol       Date:  1992-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.